SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
LaBarre Michael J.

(Last) (First) (Middle)
C/O HALOZYME THERAPEUTICS, INC.
11388 SORRENTO VALLEY ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/03/2020
3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief Technical Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 154,223 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock 02/03/2012(1) 02/03/2021 Common Stock 40,000 $7.14 D
Option to Purchase Common Stock 02/02/2013(1) 02/02/2022 Common Stock 40,000 $11.29 D
Option to Purchase Common Stock 02/04/2014(1) 02/04/2023 Common Stock 55,000 $6.55 D
Option to Purchase Common Stock 02/06/2015(1) 02/06/2024 Common Stock 37,500 $13.1 D
Option to Purchase Common Stock 02/04/2016(1) 02/04/2025 Common Stock 34,000 $13.81 D
Option to Purchase Common Stock 02/03/2017(1) 02/03/2026 Common Stock 78,452 $8.11 D
Option to Purchase Common Stock 02/22/2018(1) 02/22/2027 Common Stock 56,352 $12.07 D
Option to Purchase Common Stock 02/14/2019(1) 02/14/2028 Common Stock 40,489 $18.41 D
Option to Purchase Common Stock 07/02/2019(1) 07/02/2028 Common Stock 2,000 $16.78 D
Option to Purchase Common Stock 02/12/2020(1) 02/12/2029 Common Stock 60,146 $16.65 D
Restricted Stock Unit 02/03/2017(2) (2) Common Stock 11,559 (2) D
Restricted Stock Unit 02/22/2018(2) (2) Common Stock 17,606 (2) D
Restricted Stock Unit 02/14/2019(2) (2) Common Stock 17,314 (2) D
Restricted Stock Unit 02/12/2020(2) (2) Common Stock 31,532 (2) D
Explanation of Responses:
1. This option vests one-fourth on such date and then vests 1/48th monthly thereafter.
2. One-fourth of the original grant vests on such date and one-fourth vests annually thereafter. Represents a restricted stock unit award with no exercise price.
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
/s/ James R. Oehler as attorney-in-fact for Michael J. LaBarre 01/06/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.